Alpha-1 antitrypsin deficiency (AATD) has turned into the most crowded proving ground in genetic medicine, with five editing companies reporting fresh...
AIRNA has taken a different route to correcting the genetic lesion behind alpha-1 antitrypsin deficiency (AATD). Its oligonucleotide AIR-001 restored...
Some of the best links we picked up around the internet
Boston- and Germany-based biotech startup AIRNA is pioneering a new approach to genetic medicine by harnessing the body's natural RNA-editing...
Korro Bio has received clearance from the Australian regulatory body to initiate a Phase 1/2 trial of its RNA-editing therapeutic candiate KRRO-110 in...
